albumin-bound paclitaxel / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

109 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
albumin-bound paclitaxel / Generic mfg.
MP-PDAC-01, NCT03666832: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel

Recruiting
1b
36
RoW
TEW-7197, TEW-7197, FOLFOX
Joon Oh Park
Metastatic Pancreatic Cancer
12/22
12/23
NCT04258072: Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting
1b
24
RoW
Vactosertib, TEW-7197
Samsung Medical Center
Pancreas Cancer
12/22
03/23
NCT02930902: Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Completed
1b
9
US
Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Paricalcitol, Compound 49510, Zemplar, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7
01/23
01/23
PanCAN-SR1, NCT04581343: A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients

Checkmark Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Nov 2022 - Nov 2022: Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Active, not recruiting
1b
10
US
Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine, Ilaris, Abraxane
Pancreatic Cancer Action Network, Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
03/23
08/23
NCT05557851: Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Recruiting
1b
36
RoW
Minnelide
Minneamrita Therapeutics LLC
Metastatic Adenocarcinoma of the Pancreas
06/24
12/24
NCT03554044: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Active, not recruiting
1b
20
US
Anastrozole, Arimidex, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, ICI 182,780, ZD9238, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC, OncoVEXGM-CSF, Tamoxifen, Nolvadex, Nab paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin
University of California, San Francisco, Amgen
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
04/25
04/25
OMO-103-02, NCT06059001: Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

Recruiting
1b
18
Europe
OMO-103, Nab-Paclitaxel, Gemcitabine
Peptomyc S.L.
Metastatic Pancreatic Cancer
12/25
03/26
ACTRN12623000223639: A safety and early efficacy study of LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel, as first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)

Recruiting
1
30
 
Warpnine Incorporated, Warpnine Incorporated
Cancer
 
 
NCT03279237: A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Active, not recruiting
1
25
US
Irinotecan, Camptosar, Oxaliplatin, Eloxatin, Leucovorin, 5-Fluorouracil, Efudex, Paclitaxel, Abraxane, Radiation Therapy, Carboplatin
Massachusetts General Hospital, National Cancer Institute (NCI)
GastroEsophageal Cancer
11/18
09/23
NCT02009449: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Checkmark In combination with pembrolizumab/ nivolumab for advanced RCC
Sep 2019 - Sep 2019: In combination with pembrolizumab/ nivolumab for advanced RCC
Checkmark Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Sep 2017 - Sep 2017: Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Checkmark From AM0010/AM0010 + anti-PD-1 in NSCLC at ESMO 2017 [screenshot]
More
Active, not recruiting
1
350
US
Pegilodecakin, LY3500518, AM0010, PEGylated recombinant human Interleukin-10, PEG-rHuIL-10, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, Taxol or taxotere and paraplatin or platinol, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), Eloxatin®/Leucovorin/5-FU, gemcitabine/nab-paclitaxel, Gemzar/Abraxane ABI-007, Capecitabine, Xeloda, Pazopanib, GW786034, Pembrolizumab, Keytruda, MK-3475, Paclitaxel, nivolumab, Keytruda, Gemcitabine/carboplatin, gemzar/paraplatin
Eli Lilly and Company, ARMO BioSciences
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
02/19
08/24
NCT02495896: Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Terminated
1
61
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, nab-paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, protein-bound paclitaxel, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
University of Southern California, National Cancer Institute (NCI), Vasgene Therapeutics, Inc
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
05/19
05/19
ACTRN12618000804280: CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Active, not recruiting
1
29
 
DrugCendR Australia Pty Ltd, DrugCendR Australia Pty Ltd
Pancreatic cancer
 
 
NCT03421353: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Hourglass Jan 2019 - Dec 2020 : Data from P1b/2 trial of Imfinzi in combination with AZD9150 for NSCLC
Active, not recruiting
1
76
US
AZD9150, Durvalumab, MEDI4736, Cisplatin, 5-Flourouracil, 5-FU, Carboplatin, Gemcitabine, Nab-paclitaxel
AstraZeneca
Advanced Solid Tumours
01/20
06/24
NCT03252808: Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.

Active, not recruiting
1
36
Japan
TBI-1401(HF10), HF10, canerpaturev, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, TS-1, Tegafur-gimeracil-oteracil potassium
Takara Bio Inc.
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
02/20
03/35
NCT03307785: Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Active, not recruiting
1
58
US
Niraparib, Zejula, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, Avastin, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Tesaro, Inc.
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
02/20
08/24
NCT02937272: A Study of LY3200882 in Participants With Solid Tumors

Active, not recruiting
1
223
Europe, Canada, Japan, US, RoW
LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy
Eli Lilly and Company
Solid Tumor
02/20
08/25
NCT02336087: Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Active, not recruiting
1
21
US
Gemcitabine Hydrochloride, dFdC, dFdCyd, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, ABI 007, ABI-007, Abraxane, Metformin Hydrochloride, Glucophage, Metformin HCl, Therapeutic Dietary Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
City of Hope Medical Center, National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
10/20
12/24
ChiCTR1900027833: Gemcitabine/nab-paclitaxel/S-1 triple regimen for patients with locally advanced or advanced pancreatic cancer: A prospective, single-arm, phase I study

Recruiting
1
15
 
Initially treated patients with locally advanced or advanced pancreatic cancer will receive gemcitabine, nab-paclitaxel, and S-1 triple therapy chemotherapeutic regimen.
West China Hospital, Sichuan University; West China Hospital, Sichuan University, No
pancreatic cancer
 
 
NCT03177291: Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Active, not recruiting
1
48
US
Pirfenidone, 5-methyl-1-phenyl-1H-pyridine-one, Esbriet, Carboplatin, Paraplatin, Paclitaxel, Abraxane, Pemetrexed, Alimta
H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
05/21
06/24
NCT04046887: Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

Terminated
1
14
US
Lonsurf, Gemcitabine, Nab-Paclitaxel
Patrick Joseph Loehrer Sr., Indiana University, Taiho Oncology, Inc.
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
05/21
10/23
NCT03703063: Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Recruiting
1
30
US
Gemcitabine, Gemzar, nab paclitaxel, Abraxane, Onivyde, Leucovorin, 5-fu
Benaroya Research Institute
Pancreatic Adenocarcinoma
09/21
09/22
NCT04707118: Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Not yet recruiting
1
106
RoW
cisplatin+Nab-paclitaxel+GEM, Nab-paclitaxel+GEM
Fudan University
Advanced Pancreatic Cancer
12/21
12/22
NCT03977220: Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer

Not yet recruiting
1
20
NA
Nab-paclitaxel combined with S-1
Shanghai Zhongshan Hospital
Gastric Cancer
12/21
12/23
NCT04282070: SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
1
91
RoW
SHR-1701, SHR-1701 Injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin Injection, Albumin Paclitaxel, nab-Paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
04/22
12/22
NCT03703089: Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

Recruiting
1
21
US
Gemcitabine, GEMZAR, nab-paclitaxel, Abraxane
Benaroya Research Institute
Pancreatic Adenocarcinoma
05/22
05/23
NCT03246074: Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

Active, not recruiting
1
27
US
Fostamatinib and Paclitaxel, Fostamatinib and Abraxane
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Rigel Pharmaceuticals, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Ovarian Cancer
08/22
10/24
NCT03928314: Study of ORIC-101 in Combination With Anticancer Therapy

Terminated
1
83
US
ORIC-101, Nab-paclitaxel
ORIC Pharmaceuticals
Solid Tumor
09/22
12/23
NCT05274893: A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer

Not yet recruiting
1
28
NA
SYHX2011 and Abraxane®
CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Breast Cancer
09/22
10/22
NCT04603846: A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Active, not recruiting
1
20
RoW
anti-PD-L1 antibody, ZKAB001, albumin bound paclitaxel, ABRAXANE
Lee's Pharmaceutical Limited
Advanced Urothelial Carcinoma
10/22
08/23
NCT02999477: A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Active, not recruiting
1
50
US
Pembrolizumab, Keytruda, Nab-Paclitaxel, Abraxane, Biopsy
Adrienne G. Waks, Merck Sharp & Dohme LLC
Breast Cancer
11/22
01/26
NCT03884556: TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Hourglass Jan 2022 - Dec 2022 : Early proof of concept data from P1/1b trial for solid tumors
Completed
1
56
US
TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
Trishula Therapeutics, Inc.
Solid Tumor, Lymphoma
11/22
09/23
NCT04306900: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Completed
1
185
US, RoW
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Trishula Therapeutics, Inc., AbbVie
Solid Tumor, Adult
11/22
03/24
NCT05251766: Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer

Not yet recruiting
1
30
NA
Nab paclitaxel, Aiyue(Jiangsu Hengrui Pharmaceuticals Co.), Docetaxel, Tianlun(Yangzijiang Pharmaceuticals Co.)
Xuli Meng
Breast Cancer, Chemotherapy Effect
12/22
06/23
NCT04850235: Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study

Active, not recruiting
1
36
RoW
Nab paclitaxel
Sun Yat-sen University
Nasopharyngeal Cancer
12/22
12/24
NCT04247126: A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Completed
1
105
US
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Syros Pharmaceuticals
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
01/23
03/23
NCT04523987: A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting
1
10
RoW
Ciprofloxacin
National University Hospital, Singapore
Metastatic Pancreatic Ductal Adenocarcinoma
02/23
02/24
SGNS40-001, NCT02376699: Safety Study of SEA-CD40 in Cancer Patients

Checkmark Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Jan 2022 - Jan 2022: Data in combination with SEA-CD40 in metastatic PDAC at ASCO GI 2022
Terminated
1
159
US
Intravenous (IV) SEA-CD40, SEA-CD40, Pembrolizumab, Keytruda, Subcutaneous (SC) SEA-CD40, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane
Seagen Inc., Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
03/23
04/23
NCT04584112: A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed
1
83
Europe, US, RoW
Tiragolumab, Atezolizumab, Tecentriq, Nab-paclitaxel, Abraxane, Carboplatin, Doxorubicin, Lipodox, Doxil, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), filgrastim, pegfilgrastim, Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Hoffmann-La Roche
Triple-Negative Breast Cancer
03/23
03/23
NCT03435250: Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Hourglass Apr 2021 - Dec 2021 : From trial for advanced solid tumors or lymphoma with MTAP loss
Terminated
1
123
Europe, US
AG-270, MAT2A inhibitor, docetaxel, Taxotere®, nab-paclitaxel, Abraxane®, gemcitabine, Gemzar®
Institut de Recherches Internationales Servier
Advanced Solid Tumors, Lymphoma
04/23
04/23
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Calendar Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
NCT05157542: Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Recruiting
1
9
RoW
Durvalumab, nanoparticle albumin bound paclitaxel, low dose radiation therapy
Juan LI, MD
Stage III Non-small Cell Lung Cancer
06/23
06/23
NCT04634539: Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Active, not recruiting
1
18
US
Gemcitabine, Nab-paclitaxel, L-glutamine, Endari
Jun Gong, MD, Emmaus Medical, Inc.
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
07/23
07/25
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Not yet recruiting
1
24
NA
JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
Onconic Therapeutics Inc.
Pancreatic Ductal Adenocarcinoma
08/23
08/23
GAS, NCT06229496: Dose Escalation and Dose Expansion Study of in Subjects With Metastatic Pancreatic Adenocarcinoma

Recruiting
1
70
RoW
Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA), Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA), Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)
Chang Gung Memorial Hospital
Metastatic Pancreatic Adenocarcinoma
07/26
07/26
KEYNOTE-A62, NCT04336098: Study of SRF617 in Patients With Advanced Solid Tumors

Completed
1
85
Canada, US
SRF617, Gemcitabine, Gemzar®, Albumin-Bound Paclitaxel, Abraxane®, Pembrolizumab, Keytruda®
Coherus Biosciences, Inc., Surface Oncology, Merck Sharp & Dohme LLC
Advanced Solid Tumor
08/23
08/23
NCT06182072: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
28
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, nab paclitaxel, (G-nP)
ProDa BioTech, LLC, University of Alabama at Birmingham, Georgia State University
Pancreatic Ductal Carcinoma
07/25
10/25
UCT01097-001, NCT04761601: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Terminated
1
32
US
UCT-01-097, Gemcitabine, Gemzar, Paclitaxel, Abraxane
1200 Pharma, LLC
Advanced Solid Tumor
02/24
02/24
NCT05193604: A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Terminated
1
29
RoW
TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection, Paclitaxel for injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Pancreatic Carcinoma
11/23
11/23
NCT05881525: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Recruiting
1
18
RoW
TC-N201 cells, IL-2, Fludarabine, Cyclophosphamide, Nab-paclitaxel
TCRCure Biopharma Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumors
10/24
03/25
NCT03507491: Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Active, not recruiting
1
24
US
Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane
Emory University, Celgene Corporation
Cancer
06/24
06/24
NCT01847326: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

Active, not recruiting
1
48
US
carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, hydroxyurea, HU, HYD, Hydrea, Hydroxycarbamide, Hydurea, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation, hyperfractionated radiation therapy, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
11/27
11/27
NCT03893955: A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
150
Europe, US, RoW
ABBV-927, ABBV-368, ABBV-181, Budigalimab, Carboplatin, Nab-paclitaxel
AbbVie
Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors
09/24
09/24
NCT04297605: Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Recruiting
1
28
US
Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
University of Rochester
Non-small Cell Lung Cancer
11/24
11/24
Nab-PIPAC, NCT04000906: PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis

Active, not recruiting
1
18
Europe
Nab paclitaxel, Cisplatin
University Hospital, Geneva
Peritoneal Carcinomatosis
12/23
12/24
ChiCTR2200060165: Clinical study of camrelizumab combined with nabTC in the long-term neoadjuvant treatment of patients with stage II-III operable lung adenocarcinoma

Not yet recruiting
1
30
 
Carrilizumab + albumin-paclitaxel + carboplatin was given. After 2 weeks of treatment, the drug was stopped and lung cancer resection was performed
First Affiliated Hospital of Anhui Medical University; First Affiliated Hospital of Anhui Medical University, None
non-small cell lung cancer (NSCLC)
 
 
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
NCT06199466: A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Recruiting
1
64
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-paclitaxel, Paclitaxel, Abraxane, ABI-007, YL-13027
M.D. Anderson Cancer Center, 280Bio Inc
Metastatic Pancreatic Cancer
01/27
01/27
GASTO-10102, NCT06020885: Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Recruiting
1
18
RoW
Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemotherapy
Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
01/24
07/24
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Recruiting
1
264
US
MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
BioNTech Research & Development, Inc.
Pancreatic Cancer
08/24
10/26
NCT05648994: TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Not yet recruiting
1
30
NA
TCR-T cells, Fludarabine, Cyclophosphamide Capsules, Albumin-bound paclitaxel, IL-2
Fujian Cancer Hospital
Solid Tumors
02/24
03/26
NCT05344742: A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Not yet recruiting
1
116
NA
Mitoxantrone Hydrochloride Liposome injection, Capecitabine, Albumin-paclitaxel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
03/24
03/25
NCT06278454: Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

Not yet recruiting
1
58
RoW
NRT6008 Injection + Systematic chemotherapy
Chengdu New Radiomedicine Technology Co. LTD.
Unresectable Pancreatic Cancer
12/26
12/26
NCT05285358: Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Recruiting
1
12
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
10/28
10/28
NCT05390710: PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Completed
1
21
RoW
LAE005 + Afuresertib + Nab-Paclitaxel
Laekna Limited
Solid Tumor, TNBC - Triple-Negative Breast Cancer
12/23
12/23
NCT05438797: The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Recruiting
1
3
RoW
Adoptive TIL-TCM transfer therapy, TIL-TCM
Sizhen Wang, Shanghai Biomed-union Biotechnology Co., Ltd.
Advanced Pancreatic Cancer
04/24
04/24
NCT06326736: Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Recruiting
1
12
RoW
Surgery, Surgical resection, Camrelizumab, PD-1 inhibitor, SJ-Neo006, Neoantigen mRNA Vaccines, Gemcitabine+Abraxane, chemotherapy
Jinling Hospital, China, Jiangsu Synthgene Biotechnology Co.Ltd.
Pancreatic Cancer
12/25
12/26
FORTITUDE-201, NCT05267470: A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression

Completed
1
74
Europe, Japan, US, RoW
Bemarituzumab, AMG 552, Docetaxel, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
Amgen
Squamous-Cell Non-Small-Cell Lung Cancer
04/24
05/24
AdvanTIG-105, NCT04047862: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Checkmark Cohorts 1 & 2 data in combination with tislelizumab + chemotherapy from AdvanTIG-105 trial for squamous and non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Cohorts 1 & 2 data in combination with tislelizumab + chemotherapy from AdvanTIG-105 trial for squamous and non-squamous NSCLC at ESMO 2022
Active, not recruiting
1
449
US, RoW
Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine
BeiGene
Locally Advanced and Metastatic Solid Tumors
08/24
08/24
CHASe-PDAC, NCT06393400: CHemotherapy And Stool Transplant in PDAC

Not yet recruiting
1
20
Canada
Fecal Microbiota Transplantation, PEG3350, Gemcitabine, nab-Paclitaxel
John Lenehan
Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
02/28
02/28
NCT06360354: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Recruiting
1
282
US
AMG 193, Gemcitabine, Nab-paclitaxel, Cisplatin, Pembrolizumab, Modified FOLFIRINOX
Amgen
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
11/25
11/27
ACT, NCT04021277: PS101-mediated With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

Recruiting
1
32
Europe
20 uL/kg PS101, 40 uL/kg PS101, Ultrasound
EXACT Therapeutics AS
Solid Tumor, Colorectal Cancer
06/24
06/24
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
NCT06432075: Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer

Not yet recruiting
1
20
NA
Neoantigen Reactive T Cells(NRTs)
First Affiliated Hospital of Wenzhou Medical University
Advanced Gastric Cancer
01/26
12/26
NCT02020707: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Active, not recruiting
1
73
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Laboratory Biomarker Analysis, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Pharmacological Study
Mayo Clinic, National Cancer Institute (NCI)
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, Cervical Carcinosarcoma, Cervical Squamous Cell Carcinoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma
06/24
06/25
NCT06447662: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Not yet recruiting
1
330
US
PF-07934040, PF-4040, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, Cetuximab, Erbitux, Fluorouracil, 5-FU, 5-fluorouracil, Oxaliplatin, Eloxatin, Leucovorin, Folinic Acid, Wellcovorin, calcium folinate, Leucovorin Calcium, Bevacizumab, Zirabev, Avastin, Pembrolizumab, Pembro, Lambrolizumab, MK-3475, Keytruda, pemetrexed, Alimta, Cisplatin, Platinol, Cisplatinum, neoplatin, Paclitaxel, Taxol, Onxol, Carboplatin, Paraplatin, Stricarb
Pfizer
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
07/27
07/28
IntenSify, NCT05494866: A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
1
18
Europe
Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel
German Cancer Research Center, University Hospital Heidelberg
CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasm
08/24
02/25
NCT05300048: Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Active, not recruiting
1
68
US
Serabelisib, Insulin Suppressing Diet, Nab paclitaxel
Faeth Therapeutics
Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
09/24
09/24
MK-5890-001, NCT03396445: Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors

Checkmark Presentation of data from trial in combination with Keytruda in solid tumors at SITC 2019
Nov 2019 - Nov 2019: Presentation of data from trial in combination with Keytruda in solid tumors at SITC 2019
Active, not recruiting
1
202
Europe, US, RoW
Boserolimab, MK-5890, Pembrolizumab, MK-3475, Pemetrexed, ALIMTA®, Carboplatin, PARAPLATIN®, Nab-paclitaxel, ABRAXANE®
Merck Sharp & Dohme LLC
Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
10/24
10/24
REVOLUTION, NCT04787991: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting
1
45
US
Nivolumab (Cohort A), Opdivo, Ipilimumab (Cohort A, B and C), Yervoy, Hydroxychloroquine (HCQ) (Cohort B), Plaquenil, Nab-paclitaxel (nP) (Cohort A, B and C), Abraxane, Gemcitabine (gem) (Cohort A, B and C), Gemzar, NG350A (Cohort C)
Cancer Insight, LLC, Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Metastatic Pancreatic Adenocarcinoma
10/24
01/25
NCT05653661: Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1
40
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Nab-paclitaxel/Danburstotug Complex AP160, AP 160, AP-160, AP160, Nab-paclitaxel/STI-3031 Complex AP160
Mayo Clinic
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Melanoma
11/24
11/25
NCT05911308: Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Recruiting
1
24
US
Durvalumab, Imfinzi, Carboplatin, Paraplatin, Abequolixron, RGX 104, RGX-104, RGX104, SB-742881, Abraxane, Paclitaxel albumin-bound, Nab-paclitaxel, Pemetrexed, Alimta
UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Rgenix, Inc.
Non-Small Cell Lung Cancer
12/24
12/24
ChiCTR2200063680: An exploratory clinical study on the efficacy and safety of tirelizumab combined with gemcitabine and albumin paclitaxel in the treatment of borderline resectable pancreatic cancer

Not yet recruiting
1
30
 
Treatment programs
The Second Affiliated Hospital of the Army Medical University;, Self raised funds
Pancreatic cancer
 
 
NCT05497778: A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Recruiting
1
25
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab paclitaxel, Paclitaxel (protein-bound), Abraxane, ABI-007, IM156
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Pancreas Cancer
01/25
01/25
NCT05984602: A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Recruiting
1
10
US
Canakinumab, ACZ885, Tislelizumab, Nab-Paclitaxel, Gemcitabine
NYU Langone Health
Pancreatic Cancer
02/25
06/25
MK-0482-001, NCT03918278: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Active, not recruiting
1
230
Europe, Canada, US, RoW
MK-0482, pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin ®, Pemetrexed, Alimta
Merck Sharp & Dohme LLC
Neoplasms
02/25
02/25
NCT05685602: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Suspended
1
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Emavusertib, AU 4948, AU-4948, CA 4948, CA-4948, CA4948, Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948, IRAK4 Inhibitor CA-4948, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
03/25
03/25
FTIH, NCT03530397: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Active, not recruiting
1
401
Europe, US, RoW
MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel
MedImmune LLC
Selected Advanced Solid Tumors
12/25
12/25
K19017-004, NCT05684731: Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer

Not yet recruiting
1
30
RoW
KM1, Chemotherapy
Tongji Hospital, Qilu Hospital of Shandong University, People's Hospital of Quzhou, Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.
Ovarian Cancer
06/25
06/26
NCT06076837: The Seven Trial: Exploiting the Unfolded Protein Response

Not yet recruiting
1
12
US
Botensilimab, AGEN1811, Balstilimab, AGEN2034, Chloroquine Phosphate, Aralen, Celecoxib, Celebrex
HonorHealth Research Institute, Translational Genomics Research Institute, University of Arizona, Agenus Inc.
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
06/25
12/25
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
NCT05984342: Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

Recruiting
1
50
RoW
Tislelizumab, nab-paclitaxel, Cisplatin
Affiliated Cancer Hospital of Shantou University Medical College
Esophageal Squamous Cell Carcinoma
06/25
06/29
NCT06091943: Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
1
42
RoW
Tislelizumab IV, BGB-A317 IV, Tislelizumab SC, BGB-A317 SC, Histology-Based Chemotherapy Doublet
BeiGene
Non-small Cell Lung Cancer
07/25
03/26
ChiCTR2300074404: Cardonizumab plus Chemotherapy for the First Line Treatment of Advanced unresectable Esophageal Squamous Cell Cancer

Recruiting
1
33
 
Cardonizumab: 6mg/kg intravenous drip d1 q3w; Albumin bound paclitaxel: 260mg/m2 q3w, four cycles; Nedaplatin: 80mg/m2 iv d1 q3w four cycles.
Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital, None
Esophageal cancer
 
 
BRIO, NCT05979818: Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

Not yet recruiting
1
6
NA
Propranolol hydrochloride, Inderal, Sintilimab, Chemotherapy
Second Xiangya Hospital of Central South University, Innovent Biologics (Suzhou) Co. Ltd.
Non Small Cell Lung Cancer, Propranolol
08/25
12/26
NOVOCURE, NCT06124118: Tumor Treating Fields for Locally Advanced NSCLC

Recruiting
1
30
US
carboplatin chemotherapy, paclitaxel, nab-paclitaxel, NovoTTF-200T (TTFields) System, Durvalumab, Imfinzi
University of Utah
Non Small Cell Lung Cancer
11/25
11/26
NCT02207465: A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Recruiting
1
42
US
Radiotherapy, Abraxane, nab-paclitaxel
Abramson Cancer Center at Penn Medicine
Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy, Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy
12/25
12/25
NCT05631899: CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Recruiting
1
15
RoW
KRAS-EphA-2-CAR-DC, Abraxane, Abraxane Injectable Product, Cyclophosphamide, Cyclophosphamide for Injection, Anti-PD-1 antibody, PD-1 blocking antibody, Anti-CTLA4 Monoclonal Antibody, Ipilimumab
Chinese PLA General Hospital, Zhejiang University
Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C, KRAS G12D
12/25
12/26
NCT05631886: Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Recruiting
1
10
RoW
TP53-EphA-2-CAR-DC, Abraxane, Abraxane Injectable Product, Cyclophosphamide, Cyclophosphamide for Injection, anti-PD-1 antibody, PD-1 blocking antibody, Anti-CTLA4 Monoclonal Antibody, Ipilimumab
Chinese PLA General Hospital, Zhejiang University
Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H, TP53 R175H, TP53 R248Q, TP53 R249S
12/25
12/26
NCT05867121: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
120
Europe, Japan, US, RoW
RO7496353, SOF 10, Atezolizumab, RO554126 7; Tecentriq, Capecitabine, S-1, Tegafur/Gimeracil/Oteracil potassium, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Genentech, Inc., Chugai Pharmaceutical Co.
Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
12/25
12/25
NCT05422794: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Suspended
1
57
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475
National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
12/25
12/25
 

Download Options